{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:40:26Z","timestamp":1793176826673,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009886","name":"American Academy of Sleep Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clgc.2023.12.008","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T19:49:16Z","timestamp":1702756156000},"page":"380-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9208-9406","authenticated-orcid":false,"given":"Chitra Priya","family":"Emperumal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1986-8357","authenticated-orcid":false,"given":"Caleb","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-489X","authenticated-orcid":false,"given":"Bridget P.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clgc.2023.12.008_bib0001","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.clgc.2023.12.008_bib0002","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.008_bib0003","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"26","key":"10.1016\/j.clgc.2023.12.008_bib0004","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clgc.2023.12.008_bib0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clgc.2023.12.008_bib0006","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.008_bib0007","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1368-8375(97)00053-5","article-title":"Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity","volume":"34","author":"Sonis","year":"1998","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.008_bib0008","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12243","article-title":"Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"263","author":"Gill","year":"2015","journal-title":"Immunol Rev"},{"issue":"14","key":"10.1016\/j.clgc.2023.12.008_bib0009","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pros.23214","article-title":"Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response","volume":"76","author":"Junghans","year":"2016","journal-title":"Prostate"},{"issue":"20 Pt 1","key":"10.1016\/j.clgc.2023.12.008_bib0010","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clgc.2023.12.008_bib0011","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.008_bib0012","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified t cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clgc.2023.12.008_bib0013","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.1002\/lary.28585","article-title":"Head and neck dystonia following chimeric-antigen receptor T-cell immunotherapy: a case report","volume":"130","author":"Lee","year":"2020","journal-title":"Laryngoscope"},{"key":"10.1016\/j.clgc.2023.12.008_bib0014","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1016\/j.annonc.2020.08.869","article-title":"609O results from a phase i study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE\u00ae) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"31","author":"Tran","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2023.12.008_bib0015","doi-asserted-by":"crossref","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.008_bib0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2023.12.008_bib0017","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.clgc.2023.12.008_bib0018","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.oooo.2018.01.011","article-title":"Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET\/CT","volume":"125","author":"Klein Nulent","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.clgc.2023.12.008_bib0019","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","article-title":"The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far","volume":"98-99","author":"Heynickx","year":"2021","journal-title":"Nucl Med Biol"},{"issue":"12","key":"10.1016\/j.clgc.2023.12.008_bib0020","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2023.12.008_bib0021","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"suppl 5","key":"10.1016\/j.clgc.2023.12.008_bib0022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ajco.13057","article-title":"Advanced prostate cancer update 2018","volume":"14","author":"Sartor","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"9747","key":"10.1016\/j.clgc.2023.12.008_bib0023","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.clgc.2023.12.008_bib0024","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clgc.2023.12.008_bib0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2023.12.008_bib0026","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","article-title":"Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"suppl 6","key":"10.1016\/j.clgc.2023.12.008_bib0027","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1200\/JCO.2022.40.6_suppl.094","article-title":"Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC","volume":"40","author":"McKean","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2023.12.008_bib0028","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3390\/diagnostics12081926","article-title":"Salivary gland toxicity of PSMA-targeted radioligand therapy with (177)Lu-PSMA and combined (225)Ac- and (177)Lu-labeled PSMA ligands (TANDEM-PRLT) in advanced prostate cancer: a single-center systematic investigation","volume":"12","author":"Langbein","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"10.1016\/j.clgc.2023.12.008_bib0029","first-page":"290","article-title":"Oral mucositis complicating chemotherapy and\/or radiotherapy: options for prevention and treatment","volume":"51","author":"Kostler","year":"2001","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.clgc.2023.12.008_bib0030","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/14712598.2021.1857361","article-title":"Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy : what are we doing; where are we going?","volume":"21","author":"Bechman","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"10.1016\/j.clgc.2023.12.008_bib0031","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose (177)Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10276","key":"10.1016\/j.clgc.2023.12.008_bib0032","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clgc.2023.12.008_bib0033","first-page":"1081","article-title":"A systematic review of dysgeusia induced by cancer therapies","volume":"18","author":"Hovan","year":"2010","journal-title":"Support Care Cancer"},{"issue":"25","key":"10.1016\/j.clgc.2023.12.008_bib0034","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.21.01208","article-title":"Salivary gland hypofunction and\/or xerostomia induced by nonsurgical cancer therapies: ISOO\/MASCC\/ASCO guideline","volume":"39","author":"Mercadante","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:30:45Z","timestamp":1793176245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323002744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1558767323002744"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.12.008","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}